Literature DB >> 18837907

Cancer pain and analgesia.

Paul J Christo1, Danesh Mazloomdoost.   

Abstract

Pain ranges in prevalence from 14-100% among cancer patients and occurs in 50-70% of those in active treatment. Cancer pain may result from direct invasion of tumor into nerves, bones, soft tissue, ligaments, and fascia, and may induce visceral pain through distension and obstruction. Cancer pain is multifaceted. Clinicians may describe cancer pain as acute, chronic, nociceptive (somatic), visceral, or neuropathic. Despite implementation of the WHO guidelines, reports of undertreatment of cancer pain persist in various clinical settings and in spite of decades of work to reduce unnecessary discomfort. Substantial obstacles to adequate pain relief with opioids include specific concerns of patients themselves, their family members, physicians, nurses, and the healthcare system. The WHO analgesic ladder serves as the mainstay of treatment for the relief of cancer pain in concert with tumoricidal, surgical, interventional, radiotherapeutic, psychological, and rehabilitative modalities. This multidimensional approach offers the greatest potential for maximizing analgesia and minimizing adverse effects. Primary therapies are directed at the source of the cancer pain and may enhance a patient's function, longevity, and comfort. Adjuvant therapies include nonopioids that confer analgesic effects in certain medical conditions but primarily treat conditions that do not involve pain. Nonopioid medications (over-the-counter agents) are useful in the management of mild to moderate pain, and their continuation through step 3 of the WHO ladder is an option after weighing a drug's risks and benefits in individual patients. Symptomatic treatment of severe cancer pain should begin with an opioid, regardless of the mechanism of the pain. They are very effective analgesics, titrate easily, and offer a favorable risk/benefit ratio. Cancer pain remains inadequately controlled despite the diagnostic and therapeutic means of ensuring that patients feel comfortable during their illness. Therefore, all practitioners need to make control of cancer pain a professional duty, even if they can only use the most basic and least expensive analgesic medications, such as morphine, codeine, and acetaminophen, to reduce human suffering.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18837907     DOI: 10.1196/annals.1414.033

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  36 in total

1.  The Central Role of Glia in Pathological Pain and the Potential of Targeting the Cannabinoid 2 Receptor for Pain Relief.

Authors:  Jenny L Wilkerson; Erin D Milligan
Journal:  ISRN Anesthesiol       Date:  2011

2.  Professional survey on knowledge and clinical patterns of pain management in Spanish medical oncology.

Authors:  Yolanda Escobar Álvarez; César A Rodríguez Sánchez; Fernando Caballero Martínez; Virginia Recuero Cuervo; Carlos Camps Herrero
Journal:  Clin Transl Oncol       Date:  2010-12       Impact factor: 3.405

3.  Inadequate cancer pain management in Italian clinical trials.

Authors:  Ersilia Lucenteforte; Valentina Maggini; Raffaella Maione; Valentina Fabbroni; Carlo Tomino; Alessandro Mugelli
Journal:  Intern Emerg Med       Date:  2011-07-09       Impact factor: 3.397

4.  Spinal activation of delta opioid receptors alleviates cancer-related bone pain.

Authors:  V Otis; P Sarret; L Gendron
Journal:  Neuroscience       Date:  2011-03-31       Impact factor: 3.590

Review 5.  P2X receptors: New players in cancer pain.

Authors:  Alessia Franceschini; Elena Adinolfi
Journal:  World J Biol Chem       Date:  2014-11-26

6.  Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation.

Authors:  Peter Deibert; Carola Xander; Hubert E Blum; Gerhild Becker
Journal:  Core Evid       Date:  2010-06-15

7.  Recent advances in the treatment of pain.

Authors:  Mellar P Davis
Journal:  F1000 Med Rep       Date:  2010-08-19

8.  Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice.

Authors:  Adeline Yl Lim; Ignacio Segarra; Srikumar Chakravarthi; Sufyan Akram; John P Judson
Journal:  BMC Pharmacol       Date:  2010-10-15

9.  Effect of histone deacetylase inhibitor JNJ-26481585 in pain.

Authors:  Kathryn E Capasso; Melissa T Manners; Rehman A Quershi; Yuzhen Tian; Ruby Gao; Huijuan Hu; James E Barrett; Ahmet Sacan; Seena K Ajit
Journal:  J Mol Neurosci       Date:  2014-08-02       Impact factor: 3.444

10.  Potential protective effect of sunitinib after administration of diclofenac: biochemical and histopathological drug-drug interaction assessment in a mouse model.

Authors:  Jian Ren Tan; Srikumar Chakravarthi; John Paul Judson; Nagaraja Haleagrahara; Ignacio Segarra
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-05       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.